Comparison

Recombinant Human Osteoprotegerin/TNFRSF11B Protein (His Tag)

Item no. PKSH031716-1mg
Manufacturer Elabscience
Amount 1 mg
Quantity options 100 ug 50 ug 1 mg
Category
Type Proteins
Format Lyophilized Powder
Applications ELISA, Cell Culture
Specific against Human (Homo sapiens)
Host HEK293 cells
Conjugate/Tag HIS
Purity > 97 % as determined by reducing SDS-PAGE.
Sequence Met 1-Leu 401
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias OCIF, OPG, Osteoclastogenesis inhibitory factor, Osteoprotegerin, PDB5, TNFRSF11B, TR1 , Tumor necrosis factor receptor superfamily member 11B
Shipping Condition Cool pack
Available
Manufacturer - Category
Recombinant Proteins / Others
Manufacturer - Conjugate / Tag
C-His
Shipping Temperature
This product is provided as lyophilized powder which is shipped with ice packs.
Storage Conditions
Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Calculated Molecular Weight
45.3 kDa
Observed Molecular Weight
55 kDa
Manufacturer - Research Areas
Signal Transduction, Cardiovascular, immunology, metabolism,
Background
Osteoprotegerin or TNFRSF11B is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. Osteoprotegerin/TNFRSF11B acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. This protein may inhibit the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. Osteoprotegerin/TNFRSF11B also play a role in preventing arterial calcification, act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method.
Reconstitution
Please refer to the printed manual for detailed information.
Formulation
Lyophilized from sterile PBS, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Activity
1. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is typically 5-20 ng/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.2. Immobilized human TNFRSF11B-His at 10 μg/ml (100 μl/well) can bind human Fc-TNFSF11 with a linear ranger of 3. 125-200 ng/mL.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?